1. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks. (March 2023) Authors: Buti, M.; Wedemeyer, H.; Aleman, S.; Chulanov, V.; Morozov, V.; Sagalova, O.; Stepanova, T.; Gish, R. G; Lloyd, A.; Kaushik, A. M; Suri, V.; Manuilov, D.; Osinusi, A. O; Flaherty, J.; Pandey, S.; Singh, B.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗